Cart
sales@molnova.com
10058-F4
CAS No. 403811-55-2
10058-F4( 10058-F4 | 10058F4 | 10058 F4 )
Catalog No. M14382 CAS No. 403811-55-2
10058-F4 is a specific c-Myc inhibitor that disrupts the association between the c-Myc and Max.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 39 | In Stock |
|
| 10MG | 61 | In Stock |
|
| 25MG | 98 | In Stock |
|
| 50MG | 149 | In Stock |
|
| 100MG | 219 | In Stock |
|
| 500MG | 537 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product Name10058-F4
-
NoteResearch use only, not for human use.
-
Brief Description10058-F4 is a specific c-Myc inhibitor that disrupts the association between the c-Myc and Max.
-
Description10058-F4 is a specific c-Myc inhibitor that disrupts the association between the c-Myc and Max, inhibits HL60 cell growth with IC50 of 51 uM; arrests AML cells at G0/G1 phase, downregulates c-Myc expression and upregulates CDK inhibitors p21 and p27; induces apoptosis through activation of mitochondrial pathway shown by downregulation of Bcl-2, upregulation of Bax, release of cytoplasmic cytochrome C, and cleavage of caspase 3, 7, and 9; also induces myeloid differentiation.
-
In Vitro——
-
In Vivo——
-
Synonyms10058-F4 | 10058F4 | 10058 F4
-
PathwayCell Cycle/DNA Damage
-
Targetc-Myc
-
Recptorc-Myc-MAX
-
Research AreaCancer
-
Indication——
Chemical Information
-
CAS Number403811-55-2
-
Formula Weight249.3518
-
Molecular FormulaC12H11NOS2
-
Purity>98% (HPLC)
-
SolubilityDMSO: ≥ 41 mg/mL
-
SMILESO=C1NC(S/C1=C/C2=CC=C(CC)C=C2)=S
-
Chemical Name4-Thiazolidinone, 5-[(4-ethylphenyl)methylene]-2-thioxo-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
-
CBL0137
CBL0137 (Curaxin CBL0137) is a histone chaperone FACT (facilitates chromatin transcription) and MYC signal inhibitor that markedly reduced tumor initiation and progression in vivo.
-
BET bromodomain inhi...
CPI-0610 is a potent, selective, and cell-active BET bromodomain inhibitor CPI-0610 inhibits BRD4-BD1 with IC50 of 39 nM in time-resolved fluorescence energy transfer (TR-FRET ) binding assay.
-
MYCi975
MYCi975 is an orally active inhibitor of MYC.MYCi975 inhibits P493-6, MV411,SK-N-B2 cells viability in an MYC-dependent manner(IC50s of 3.7, 3.9, 6.4 μM, respectively).The initial lead, MYC inhibitor 361 (MYCi361), suppressed in vivo tumor growth in mice, increased tumor immune cell infiltration, upregulated PD-L1 on tumors, and sensitized tumors to anti-PD1 immunotherapy. However, 361 demonstrated a narrow therapeutic index.
